Debra Madden

Debra Madden is a 2-time cancer survivor who was diagnosed with Hodgkin's lymphoma as a young adult and breast cancer nearly 20 years later, which was thought to be secondary to the radiation she had received for her original cancer treatment. Debra became an active Cancer Research Advocate following her second cancer diagnosis at the age of 42 years. She is currently a member of the ECOG/ACRIN Cancer Research Group and the Patient-Centered Outcomes Research Institute's Advisory Panel on the Assessment of Prevention, Diagnosis, and Treatment Options. She also serves on multiple grant review panels, including the Congressionally Directed Medical Research Program Breast Cancer Research Program. Debra blogs at "Musings of a Cancer Research Advocate", (https://draemadden.wordpress.com/) and you can follow her on Twitter at @AdvocateDebM.
November 22, 2016
An interview with geneticist and pathologist Gabriel Bien-Willner, MD, PhD, FCAP, on why we need to change our outlook toward precision medicine in oncology.
June 18, 2016
Why this patient advocate is concerned about the newly proposed Medicare Part B model regarding its level of transparency and the evidence.
June 17, 2016
Why this patient advocate is concerned about the newly proposed Medicare Part B model regarding its level of transparency and the evidence.
June 16, 2016
Why this patient advocate is concerned about the newly proposed Medicare Part B model regarding its level of transparency and the evidence.
April 05, 2016
It is imperative that we gather more mature data on a much larger number of patients to accurately assess efficacy, safety, potential harms, durability of response, and impact on disease progression and overall survival of the new immunotherapy treatments.
March 29, 2016
It is imperative that we gather more mature data on a much larger number of patients to accurately assess efficacy, safety, potential harms, durability of response, and impact on disease progression and overall survival of the new immunotherapy treatments.
October 01, 2015
My visit to the gynecologist's office following treatment for breast cancer and a subsequent reconstructive surgery was a rude awakening.
September 29, 2015
My visit to the gynecologist's office following treatment for breast cancer and a subsequent reconstructive surgery was a rude awakening.
July 08, 2015
In part 1 of "First Do No Harm," Ms Madden noted important new research suggesting that the majority of patients with HER2+ breast cancer who are treated with the anti-HER2 agent trastuzumab do not receive sufficient cardiac monitoring. In part 2, she discusses the implications of this recent study for patients with this aggressive form of breast cancer and protective strategies against preventable harms of their treatment.
July 02, 2015
With a growing understanding of the risk of cardiotoxicity associated with cancer treatment, cardio-oncology has emerged as an important subspecialty, resulting in the establishment of cardio-oncology programs most often based at or in collaboration with comprehensive cancer centers.
Copyright AJMC 2006-2018 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
×

Sign In

Not a member? Sign up now!